He Yu: The new drug application for the oral small molecule KRAS G12D inhibitor ABSK141 has been approved by the National Medical Products Administration.

On December 24, Hu Yu announced in the Hong Kong Stock Exchange that its subsidiary, Shanghai Hu Yu Biomedical Technology Co., Ltd., announced that its oral, highly active, highly selective small molecule KRAS G12D inhibitor ABSK141 for the treatment of advanced solid tumor patients carrying KRAS G12D mutations has obtained approval for new drug clinical trial application from the China National Medical Products Administration.